BACKGROUND: Regulatory elements may be involved in the mechanisms by which 52 loci influence myocardial mass, reflected by abnormal amplitude and duration of the QRS complex on the ECG. Functional annotation thus far did not take into account how these elements are affected in disease context.
T he QRS complex on the ECG represents cardiac depolarization and conduction of the electrical signal through the ventricular muscle. Duration and amplitude of the QRS complex are used as a proxy for left ventricular mass. 1, 2 Abnormalities of the QRS complex are associated with an increased risk of cardiovascular mortality and morbidity. 3, 4 A recent large-scale GWAS (genome-wide association study) meta-analysis of 4 correlated and clinically used QRS traits (Sokolow-Lyon, Cornell, 12-lead-voltage duration products [12-leadsum] , and QRS duration) identified 52 independent loci at P<1×10 −8 . 5 However, the identification of causal variants, their target genes, and disturbed mechanisms remain an important challenge. In a given GWAS locus, the single nucleotide polymorphism (SNP) with the most significant association with the disease (lowest P value) is usually reported as the lead SNP. This lead SNP is not necessarily the causal variant, and an SNP in high linkage disequilibrium (LD) with the lead SNP may be the causal one. 6 Only 3 of the 52 SNPs reported in the original study are located in coding regions of the genome. 5 A nonsynonymous variant in high LD with a high deleteriousness score, such as Combined Annotation Dependent Depletion score >12.37, 7 can also be considered a candidate for causality, and that is the case of 14 variants in 9 QRS-associated loci (Table I in the Data Supplement). Potential mechanisms for causality in the remaining loci include disturbance of regulatory elements, genomic regions that play a crucial role in transcriptional regulation. Indeed, increasing evidence shows multiple GWAS variants regulate transcription. 8, 9 Noncoding variants often affect gene expression in a cell-type specific manner by altering the function of enhancer and promoter elements. 10, 11 Results from in silico analyses have suggested strong enrichment of QRSassociated variants in specific chromatin states associated with active enhancers, promoters, and transcription in the human heart. 12 By contrast, no enrichment was observed for transcriptionally repressive histone marks. 5, 13 Although using relevant cell-types, these previous studies did not include regulatory information obtained from tissue in disease state. Highlighting possible differences in transcription from control to diseased myocardial tissue may help understand the underlying mechanisms of changes in left ventricular mass. To gain insight into these mechanisms, we integrate genome, regulome, and transcriptome information to test whether regions differentially affected in disease can be more informative than the regulatory landscape of nondiseased tissue. We use regulatory information obtained from nondiseased myocardium and diseased tissue from patients with hypertrophic cardiomyopathy (HCM). We also colocalize candidate causative QRS-associated variants and regulatory regions that show differential activity (proxied by H3K27ac levels or by gene expression) in HCM tissues compared with controls, to identify regulatory elements potentially altered by the variation. Taken together, our results may enhance our understanding on the regulatory mechanisms underlying increased myocardial mass.
METHODS
The procedures for obtaining human samples were approved by the scientific advisory board of the biobank of the University Medical Center Utrecht (protocol number 12/387), the Washington University School of Medicine Ethics Committee (Institutional Review Board) and the local ethics committee of the Erasmus MC, and written consent was obtained. Biopsies on HCM patients are septal myomectomy specimens. Control samples were obtained from donor hearts not used for transplantation. Mutation and clinical data of patients are given in Table 1 .
Because of the sensitive nature of the data collected for this study, requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to the corresponding author at f.w.asselbergs@ umcutrecht.nl. The methods of our study are detailed in the Data Supplement.
RESULTS
In this study, we functionally annotated and fine-mapped 52 QRS-associated loci. We used regulatory information (promoters from RNA-seq experiments, H3K27ac regions highlighting active promoters and enhancers, and superenhancers from ChIP-seq experiments) obtained from nondiseased myocardium and diseased tissue from HCM patients ( Table 1; Table II . Promoter, enhancer, and super-enhancer regions were further narrowed down to those overlapping regions of open chromatin, to retain only sequences accessible to transcription factor binding. We used these regulatory features to test the enrichment of QRS-associated variants and vicinity in LD. To identify an optimal LD cutoff, we identified variants in LD with the 52 QRSassociated SNPs, and divided them into bins, as described in the Methods section. We overlapped each bin with regulatory elements differentially regulated/acetylated in HCM and performed 10k permutation tests to calculate enrichment ( Figure I in the Data Supplement). Although LD thresholds showed fluctuations on enrichment, we observed a continuous decrease in enrichment as the LD threshold becomes more lenient. We defined LD r 2 >0.5 as cutoff to expand the set of candidate causal QRSassociated variants, from 52 lead SNPs to 4620 SNPs. We colocalized these candidate causal QRS-associated variants and regulatory regions that show differential activity in disease, to identify regulatory elements potentially altered by the variation. We also investigated which set of regulatory features showed more enrichment for QRSassociated variants and thus has the potential to be more informative for fine-mapping efforts.
Disease-Affected Regulatory Regions Show More Enrichment for QRSAssociated Variants Than All TissueSpecific Regulatory Regions Identified in Control and Disease Patients
We performed enrichment tests aiming to identify which set of regulatory regions is more informative for fine-mapping efforts. Regulatory features differentially regulated/acetylated in HCM were more enriched (P=8.6×10 −5 ) than those not showing dif- ferential activity (P=0.01), suggesting these can offer more insight into mechanisms altered by genetic variation than general tissue-specific regulatory elements ( Figure 1A ).
Promoters of Differentially Expressed Genes Show More Enrichment Than Regions Highlighted by Differential Acetylation
Given the strong enrichment of QRS-associated variants in differentially regulated promoters and differentially acetylated regulatory elements in HCM ( Figure 1A) , we overlapped candidate causative SNPs and enriched regulatory features to identify variants that might be altering the function of these elements. Of the 4620 candidates QRS-associated SNPs, 74 colocalized with differential regulatory features (Figures 1 and 2 ; Table I in the Data Supplement), more than expected by chance (P=8.6×10 −5 ). These variants show more enrichment in differentially expressed promoters from RNAseq experiments (P=0.001) than differentially acetylated regulatory elements highlighted by H3K27ac from ChIPseq experiments (enhancers P=0.8, super-enhancers P=0.02; Figure 1B) . These results highlight the potential of integrating regulatory elements that show differential behavior in disease, especially promoter regions.
Fine-Mapping Pinpoints Potential Causal Variants and Candidate Genes
The 74 variants overlapping regulatory elements affected in HCM are spread through 20 QRS-associated loci (Figures II through XXI in the Data Supplement). We investigated which genes are the potential targets of the 74 QRS-associated variants. We retrieved the 3 genes nearest to each of the 74 variants. We found 13 of the nearest genes are down-regulated and 12 are up-regulated in HCM versus controls (Table I in 14 confirmed the involvement of these differentially regulated genes with QRS-associated candidate regulatory variants in 3 loci (ACP2/MADD, FADS1/FADS2, and PROCR/ EDEM2). Eighteen of the 68 candidate genes that were identified by the original study were confirmed with this new approach. 5 The functional annotation performed in this study pinpoints the likely regulatory elements affected by the variation that in turn affect expression of these genes, as well as candidate causative SNPs (Tables I and VII in the Data Supplement). The function of the new 14 candidate genes potentially involved in myocardial mass is described in Table 2 . Visualization and further description of each of the 20 QRS-associated loci overlapping regulatory regions of interest can be found on the Material in the Data Supplement. ) for QRS-associated candidate causal variants than those not showing differential activity (P=0.01). B, Promoters of genes differentially regulated between HCM patients and controls showed more enrichment (P=0.001) for QRS-associated variants than differentially acetylated enhancers (P=0.8) and superenhancers (P=0.025).
DISCUSSION
We performed functional annotation of 52 loci influencing myocardial mass, considering regulatory elements with differential activity between diseased (HCM) heart samples and control donors may act as mediators between genetic variation and gene expression. The 52 QRS-associated variants showed enrichment on the set of differential regulatory elements in comparison to nondifferential regulatory elements. In addition, differentially expressed promoters identified by RNA-seq in HCM and controls showed more enrichment of QRS-associated variants, than the other differential regulatory elements analyzed. These results can aid the study design of future fine-mapping studies.
Our functional annotation showed 20 loci overlapping with the enriched differential regulatory regions. We identified the variants in LD with the lead QRSassociated SNP overlapping regulatory features, thus pinpointing the potential causative variants and mechanisms through which these variants account risk for disease. We observed that some loci showed enrichment of more than one candidate SNP in the same regulatory feature. Studies indeed show that several variants can be causal inside a disease-associated locus. 32, 33 In addition, more than one gene can be causal inside the same loci, 34 and we indeed identified more than one candidate gene per locus in some cases. Further assays, such as chromatin conformation capture, [35] [36] [37] [38] [39] can add evidence on the interaction between QRS-candidate regulatory SNPs and each candidate gene, preferably 
PROCR-Endothelial protein C receptor
The protein encoded by this gene is a receptor for activated protein C, a serine protease activated by and involved in the blood coagulation pathway. The encoded protein is an N-glycosylated type I membrane protein that enhances the activation of protein C. Mutations in this gene have been associated with venous thromboembolism, myocardial infarction and coronary artery disease.
18,19
PRKCD-Protein kinase C delta Protein kinase C (PKC) is a family of serine-and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. Studies both in human and mice demonstrate that PRKCD kinase is involved in B cell signaling and in the regulation of growth, apoptosis, and differentiation of a variety of cell types.
20

CORO6-Coronin 6
Involved in actin filament binding. Overexpressed in heart and skeletal muscle. 21 Has been implicated in previous GWAS in coronary artery disease.
18
TCEA3-Transcription Elongation Factor A3
This gene is associated to other measure of amplitude of the ECG, ST-T wave 22 and QT-interval. 23 Overexpressed in heart.
21
FUT11-Fucosyltransferase 11
Function unknown.
CENPA-Centromere protein A Histone H3-like variant which exclusively replaces conventional H3 in the nucleosome core of centromeric chromatin at the inner plate of the kinetochore. 24 Required for recruitment and assembly of kinetochore proteins, mitotic progression and chromosome segregation. May serve as an epigenetic mark that propagates centromere identity through replication and cell division.
24-27
AGBL5-ATP/GTP binding protein-like 5
Function unknown. 
KCNK3-Potassium
KHK--ketohexokinase
Catalyzes the first step of metabolism of dietary fructose, conversion of fructose to fructose-1-phosphate. It has been shown that myocardial hypoxia influences fructose metabolism in human and mouse models of pathological cardiac hypertrophy through hypoxia-inducible factor 1-alpha activation of SF3B1 and SF3B1-mediated splice switching of KHK-A to KHK-C. 29, 30 In mice, heart-specific depletion of SF3B1 or genetic ablation of KHK suppressed pathological stress-induced fructose metabolism, growth, and contractile dysfunction. also taking into account the disease context. 40 These experiments can also reveal whether regions identified as promoters also function as enhancers. [41] [42] [43] Moreover, genes potentially influenced by the regulatory elements affected by QRS-associated variants that are not in the immediate vicinity can also be detected. 44 We observed that 18 genes mapped by the previous study were confirmed by differential expression and expression quantitative trait loci mapping, adding evidence for the role of these genes in natural variance in myocardial mass. We also identified 14 genes not previously mapped to the QRS-associated variants, some with known cardiac function and previously implicated in studies on ECG parameters and heart phenotypes. Definitive assignment of function(s) to putative cisregulatory elements requires perturbation of these elements. 45 A promising approach is deletion and manipulation of nucleases through CRISPR/Cas9, which was successful in recent studies. 10, 46 Future efforts can unravel the mechanisms of the remaining QRS-associated loci by also taking into account other regulatory elements apart from enhancers and promoters, such as silencers, highlighted by different histone modifications. In addition, other histone modifications can also help identify additional enhancer elements. A subset of active enhancers has been identified in mouse embryonic stem cells that lack H3K27ac but are marked by H3K122ac and H3K64ac, H3K4me1 and enhancer RNAs. 47 This evidence shows that although H3K27ac highlights enhancer activity, enhancers that lack H3K27ac are not necessarily inactive, and other histone marks can carry out the activating role of H3K27ac. 48 Moreover, as chromatin states are spatially and temporally dynamic along disease progression, regulatory information is needed in more different conditions including different stages of disease progression. This will allow a more precise and complete fine-mapping and functional annotation. It can also help answer whether QRS-associated SNPs promote aberrant function of regulatory elements, or the SNPs alter the activity of regulatory elements following disease establishment. Finally, the low number of control heart samples included in our ChIP-seq experiments might partly explain the lower degree of enrichment for enhancer/ superenhancer regions as compared to the promoter regions identified from RNA-seq experiments. Increas- We expanded the search from 52 lead SNPs to include variants in linkage disequilibrium (LD; r 2 >0.5), leading to 4620 candidate variants. Of these, 74 overlapped one or more regulatory feature of interest: differentially acetylated (H3K27ac) regions between hypertrophic cardiomyopathy (HCM) and control patients, differentially expressed promoter regions between HCM and control patients, and superenhancers specific to HCM or left ventricle (LV). In the 20 loci where these overlaps were observed, differential expression analysis on HCM patients and controls and expression quantitative trait loci mapping in LV identified 32 candidate genes. Eighteen of these validate the findings of the previous study, 5 now also pinpointing causal variants and the potential mechanisms by which they account risk. In addition, 14 new candidate genes were identified, some with cardiac function and previously implicated in other studies on ECG traits (Table 2; Tables I and VII in the Data Supplement). ing sample sizes may help unravel more regulatory regions and their enrichment for QRS-associated variants.
Taken together, our results show the importance of using differential regulatory elements in disease tissue on fine-mapping studies because influence from cell conditions are crucial for epigenetic modifications, chromatin accessibility, transcription factor binding, and consequently gene regulation. 49 We also expand the view of the epigenetic and regulatory aspects involved in myocardial mass by pinpointing potential causal variants, mechanisms potentially affected by genetic variation, and candidate genes. Validation of the identified candidate causal variants through methods such as genomeediting technologies will broaden our knowledge on how QRS-associated variants contribute to disease.
